Patent Games in the Global South

Amaka Vanni holds a PhD in International Economic Law from the University of Warwick and is a legal scholar and documentary filmmaker based in Lagos, Nigeria.

• 1. General Overview I. Introduction II. Terminology III. Why Brazil and India? IV. Book Outline 2. Understanding Patents I. Introduction II. The National Phase III. The Multilateral Phase – The Paris Convention IV. The Global Phase – TRIPS Agreement V. Conclusion 3. Views from the South: Critical Approaches to the Global Patent Regime I. Introduction Part I: TWAIL Theory II. Understanding TWAIL III. Situating TWAIL within the Global Patent Regime IV. Reading TRIPS Text through Twailian Lens V. Mind the Gap: On Limitations of TWAIL Part II: Nodal Governance VI. Understanding Nodal Governance VII. Nodal Governance and the Pharmaceutical Patent Regime VIII. Application of Nodal Governance to this Study IX. Conclusion 4. Brazil – The Juridical State I. Introduction II. Historical Evolution of the Patent Regime in Brazil III. Unpacking the Industrial Property Law of Brazil IV. The Constitutional Right to Health V. Resistance from Below: Social Movement and Patent Law VI. Engaging with the World: Towards Development VII. Conclusion 5. India: From Little Acorns to Mighty Oaks I. Introduction II. Historical Evolution of Patent Law in India III. Development and Competing Interests IV. Indian Patents (Amendment) Act of 2005: Unpacking Key Issues V. Medicine Access and the Nation-State as Site of Global Struggles VI. Conclusion 6. Nigeria: Disconnects, Discontinuities and the Spectacle of Reform I. Introduction II. Historical Evolution of the Patent Regime in Nigeria III. Unpacking the Patents and Designs Act of 1990 IV. State Regulatory Agencies and Patent Regime V. Patent Law-making and Nigerian Pharmaceutical Manufacturing Sector VI. Conclusion 7. General Conclusions I. Appraising the Discussion II. What is the Way Forward for Nigeria?

[T]his book is an original masterpiece that could be relied upon by a cross-section of students, scholars, researchers, policymakers, practitioners, professionals, and other stakeholders interested in the imperative but mostly esoteric and multifaceted matters of pharmaceutical patent law-making.